Page last updated: 2024-09-03
u 92032 and sun n8075
u 92032 has been researched along with sun n8075 in 1 studies
Compound Research Comparison
| Studies (u 92032) | Trials (u 92032) | Recent Studies (post-2010) (u 92032) | Studies (sun n8075) | Trials (sun n8075) | Recent Studies (post-2010) (sun n8075) |
|---|---|---|---|---|---|
| 9 | 0 | 1 | 9 | 0 | 4 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Annoura, H; Imajo, S; Miyajima, A; Nakanishi, K; Takemoto, N; Tamura, S; Tamura-Horikawa, Y; Toba, T | 1 |
Other Studies
1 other study(ies) available for u 92032 and sun n8075
| Article | Year |
|---|---|
Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a dual Na(+) and Ca(2+) channel blocker with antioxidant activity.
Topics: Acoustic Stimulation; Aniline Compounds; Animals; Anticonvulsants; Antioxidants; Calcium Channel Blockers; Cerebral Cortex; In Vitro Techniques; Lipid Peroxidation; Mice; Mice, Inbred DBA; Models, Molecular; Molecular Conformation; Neuroprotective Agents; Piperazines; Rats; Seizures; Sodium Channel Blockers | 2000 |